Park Edge Advisors LLC Acquires New Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Park Edge Advisors LLC bought a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,116 shares of the medical equipment provider’s stock, valued at approximately $583,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Berbice Capital Management LLC bought a new stake in Intuitive Surgical in the 4th quarter worth approximately $26,000. Godsey & Gibb Inc. boosted its stake in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares during the last quarter. MidAtlantic Capital Management Inc. purchased a new stake in Intuitive Surgical during the third quarter valued at $33,000. Decker Retirement Planning Inc. bought a new position in Intuitive Surgical in the fourth quarter valued at about $36,000. Finally, Capital Performance Advisors LLP purchased a new position in Intuitive Surgical in the third quarter worth about $38,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Intuitive Surgical stock opened at $584.05 on Friday. The firm’s 50 day moving average price is $547.16 and its 200-day moving average price is $504.35. Intuitive Surgical, Inc. has a 1 year low of $364.17 and a 1 year high of $616.00. The stock has a market cap of $208.03 billion, a P/E ratio of 93.90, a PEG ratio of 5.19 and a beta of 1.39.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research report on Friday. Morgan Stanley upgraded shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $522.00 to $650.00 in a research report on Monday, December 2nd. Leerink Partners boosted their price objective on shares of Intuitive Surgical from $489.00 to $502.00 in a research report on Thursday, October 17th. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Finally, The Goldman Sachs Group set a $604.00 price target on Intuitive Surgical in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $583.83.

Insider Buying and Selling at Intuitive Surgical

In other news, CFO Jamie Samath sold 270 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total transaction of $145,840.50. Following the completion of the transaction, the chief financial officer now directly owns 8,757 shares in the company, valued at approximately $4,730,093.55. This represents a 2.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Gary S. Guthart sold 18,151 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the sale, the chief executive officer now directly owns 24,219 shares in the company, valued at approximately $12,391,166.97. The trade was a 42.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,475 shares of company stock worth $22,070,807. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.